MedTrace Logo

An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer

NCT05712473 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-02-03

No results posted yet for this study

Summary

The goal of this observational research is to assess the real-world clinical utility of PYLARIFY PET through evaluation of long-term outcomes for prostate cancer patients who are eligible for a PSMA/PET scan.

Participants will be enrolled at their physician's office at the time of referral for PYLARIFY PET and will be followed for up to 5 years. Data concerning their prostate cancer diagnostics and treatment will be collected at 6-month intervals.

Conditions

Interventions

DIAGNOSTIC_TEST

PYLARIFY

PYLARIFY PET

Sponsors & Collaborators

  • Lantheus Medical Imaging

    collaborator INDUSTRY

  • Specialty Networks Research.

    lead NETWORK

Eligibility

Min Age
21 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2028-12-31
Completion
2029-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05712473 on ClinicalTrials.gov